Compare Indoco Remedies with Bajaj Finance - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

INDOCO REMEDIES vs BAJAJ FINANCE - Comparison Results

INDOCO REMEDIES     Change

Indoco Remedies is engaged in the manufacturing and marketing of formulations and active pharmaceutical ingredients (APIs) for domestic as well as the international markets. The company's focus areas include anti-infective, respiratory, anti-diabetic... More

BAJAJ FINANCE 
   Change

Established in 1987, Bajaj Finance Ltd is a subsidiary of Bajaj Finserv Ltd, the financial services arm of the Bajaj Group. In the early days, Bajaj Finance provided loans for two and three-wheelers manufactured by Bajaj Auto Ltd. Over the years, the... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    INDOCO REMEDIES BAJAJ FINANCE INDOCO REMEDIES/
BAJAJ FINANCE
 
P/E (TTM) x 51.1 51.6 99.1% View Chart
P/BV x 2.0 13.6 14.8% View Chart
Dividend Yield % 0.7 0.1 709.7%  

Financials

 INDOCO REMEDIES   BAJAJ FINANCE
EQUITY SHARE DATA
    INDOCO REMEDIES
Mar-18
BAJAJ FINANCE
Mar-18
INDOCO REMEDIES/
BAJAJ FINANCE
5-Yr Chart
Click to enlarge
High Rs3171,989 16.0%   
Low Rs1781,153 15.5%   
Sales per share (Unadj.) Rs113.11,168.6 9.7%  
Earnings per share (Unadj.) Rs4.5232.5 1.9%  
Cash flow per share (Unadj.) Rs11.8241.3 4.9%  
Dividends per share (Unadj.) Rs1.004.00 25.0%  
Dividend yield (eoy) %0.40.3 158.5%  
Book value per share (Unadj.) Rs73.21,438.4 5.1%  
Shares outstanding (eoy) m92.15115.03 80.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.21.3 163.0%   
Avg P/E ratio x55.56.8 820.9%  
P/CF ratio (eoy) x21.06.5 322.2%  
Price / Book Value ratio x3.41.1 309.7%  
Dividend payout %22.41.7 1,301.2%   
Avg Mkt Cap Rs m22,830180,689 12.6%   
No. of employees `0005.515.3 35.7%   
Total wages/salary Rs m2,20914,196 15.6%   
Avg. sales/employee Rs Th1,910.18,805.2 21.7%   
Avg. wages/employee Rs Th405.0929.9 43.5%   
Avg. net profit/employee Rs Th75.51,751.7 4.3%   
INCOME DATA
Net Sales Rs m10,419134,420 7.8%  
Other income Rs m47239 19.6%   
Total revenues Rs m10,466134,659 7.8%   
Gross profit Rs m1,34988,087 1.5%  
Depreciation Rs m6771,021 66.3%   
Interest Rs m23546,343 0.5%   
Profit before tax Rs m48440,962 1.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m7214,221 0.5%   
Profit after tax Rs m41226,741 1.5%  
Gross profit margin %12.965.5 19.8%  
Effective tax rate %15.034.7 43.1%   
Net profit margin %4.019.9 19.9%  
BALANCE SHEET DATA
Current assets Rs m5,373377,806 1.4%   
Current liabilities Rs m4,157227,458 1.8%   
Net working cap to sales %11.7111.8 10.4%  
Current ratio x1.31.7 77.8%  
Inventory Days Days680-  
Debtors Days Days73932 7.8%  
Net fixed assets Rs m6,2444,670 133.7%   
Share capital Rs m1841,150 16.0%   
"Free" reserves Rs m6,566164,306 4.0%   
Net worth Rs m6,750165,457 4.1%   
Long term debt Rs m1,233458,963 0.3%   
Total assets Rs m12,363868,243 1.4%  
Interest coverage x3.11.9 162.4%   
Debt to equity ratio x0.22.8 6.6%  
Sales to assets ratio x0.80.2 544.4%   
Return on assets %5.28.4 62.1%  
Return on equity %6.116.2 37.7%  
Return on capital %9.014.0 64.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m3,7620-   
Fx outflow Rs m1,143315 362.5%   
Net fx Rs m2,619-315 -830.3%   
CASH FLOW
From Operations Rs m1,227-204,614 -0.6%  
From Investments Rs m-1,3609,712 -14.0%  
From Financial Activity Rs m-388195,033 -0.2%  
Net Cashflow Rs m-521131 -397.7%  

Share Holding

Indian Promoters % 59.2 61.6 96.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 12.5 7.1 176.1%  
FIIs % 6.0 12.2 49.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.4 19.1 117.3%  
Shareholders   12,805 19,952 64.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare INDOCO REMEDIES With:   NESCO  TIL  S.P. APPARELS  CREST VENTURES  CCL INTERNATIONAL  



Today's Market

Sensex Ends 21 Points Higher; Banking and Oil & Gas Stocks Witness Buying(Closing)

Indian share markets witnessed buying interest during closing hours today and ended their day marginally higher.

Related Views on News

INDOCO REMEDIES Announces Quarterly Results (2QFY20); Net Profit Up 194.1% (Quarterly Result Update)

Nov 5, 2019 | Updated on Nov 5, 2019

For the quarter ended September 2019, INDOCO REMEDIES has posted a net profit of Rs 73 m (up 194.1% YoY). Sales on the other hand came in at Rs 3 bn (up 23.9% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.

BAJAJ FINANCE Announces Quarterly Results (1QFY20); Net Profit Up 43.0% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, BAJAJ FINANCE has posted a net profit of Rs 12 bn (up 43.0% YoY). Sales on the other hand came in at Rs 58 bn (up 47.4% YoY). Read on for a complete analysis of BAJAJ FINANCE's quarterly results.

INDOCO REMEDIES Announces Quarterly Results (1QFY20); Net Profit Up 118.1% (Quarterly Result Update)

Aug 14, 2019 | Updated on Aug 14, 2019

For the quarter ended June 2019, INDOCO REMEDIES has posted a net profit of Rs 22 m (up 118.1% YoY). Sales on the other hand came in at Rs 3 bn (up 16.2% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.

INDOCO REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 43.3% (Quarterly Result Update)

Jun 6, 2019 | Updated on Jun 6, 2019

For the quarter ended March 2019, INDOCO REMEDIES has posted a net profit of Rs 116 m (down 43.3% YoY). Sales on the other hand came in at Rs 3 bn (down 6.5% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.

INDOCO REMEDIES 2017-18 Annual Report Analysis (Annual Result Update)

Mar 28, 2019 | Updated on Mar 28, 2019

Here's an analysis of the annual report of INDOCO REMEDIES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of INDOCO REMEDIES. Also includes updates on the valuation of INDOCO REMEDIES.

More Views on News

Most Popular

Is Hawkins Set to Become Our Next Superhero Stock?(The 5 Minute Wrapup)

Nov 1, 2019

After PI Industries, Hawkins has put up a stellar show so far.

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

Ditch the Risky Fixed Deposits for Safer 'Bluechip Deposits'(Profit Hunter)

Oct 30, 2019

Most people think stocks are riskier than fixed deposits and bonds. The last quarter century proves otherwise.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

What to Buy at Sensex 40,000(The 5 Minute Wrapup)

Nov 4, 2019

Should you invest in high-quality, safe stocks or make some contrarian bets in the smallcap space?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

INDOCO REMEDIES SHARE PRICE


Nov 11, 2019 (Close)

TRACK INDOCO REMEDIES

  • Track your investment in INDOCO REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON INDOCO REMEDIES

INDOCO REMEDIES 5-YR ANALYSIS

COMPARE INDOCO REMEDIES WITH

MARKET STATS